90 Seconds With… Steven Yatomi-Clarke, Prescient Therapeutics (ASX:PTX)

Stockheads

31 Aug 2022

Link copied to clipboard

Got 90 seconds? Then listen to CEO & managing director, Steven Yatomi-Clarke tell us about their company news.

Prescient Therapeutics (ASX:PTX) develop novel, personalised therapies for a range of cancers.

The company has a broad pipeline of personalised cancer treatments, comprising CAR-T and targeted therapies, for a range of different cancers. With licensed technologies from and in collaboration with world-leading cancer centers in the US and Australia.

In August Prescient signed a deal with Thermo Fisher Scientific to accelerate development and commercialisation of the OmniCAR platform.

Thermo Fisher is a world leader in cell and gene technologies, and the agreement’s development plan will evaluate the potential of using automated, closed cell therapy solutions to develop a novel process of manufacturing cell therapies on Prescient’s OmniCAR platform using non-viral methods.

We gave Steven Yatomi-Clarke, CEO & Managing Director of Prescient Therapeutics, 90 seconds to tell us more about the recent announcement

Have a good idea for our next 90 Seconds With segment? Email us at [email protected]

Read MoreAusbiotechBiotechHealth

Link copied to clipboard

SUBSCRIBE

Get the latest Stockhead news delivered free to your inbox.

"*" indicates required fields

It's free. Unsubscribe whenever you want.

Read our privacy policy

Featured Companies

ASX: PTX Prescient Therapeutics

You might be interested in

90 Seconds With...

90 Seconds With… Steven Yatomi-Clarke from Prescient Therapeutics (ASX:PTX)

August 10, 2021 | Stockhead TV

StockTalk

ASX small caps leading the fight against cancer

October 8, 2020 | Dr. Nigel Finch

Trending

Health & Biotech

ASX Health Stocks: Immutep now patently Japanese; Patrys preps Phase 1 trial of brain cancer drug

August 30, 2022 | Eddy Sunarto

Sponsored Articles

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2263104414"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2263104414\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2263104414?lang=en_US&edition=fundamental","thumbnail":"https://stockhead.com.au/wp-content/uploads/2022/08/90SW-Prescient-Therapeutics-Thumbnail-640x360.jpg","is_english":true,"pubTime":"2022-08-31 03:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2263104414","market":"us","top_or_hot":-1,"title":"90 Seconds With… Steven Yatomi-Clarke, Prescient Therapeutics (ASX:PTX)","media":"Stockheads","content":"<html><body><div>\n<main role=\"main\">\n<div><div></div></div>\n<div><div><img height=\"40\" src=\"https://stockhead.com.au/wp-content/themes/stockhead_lee_mic_v2/images/social-share/check-icon.png\" width=\"40\"/></div><div><p>Link copied to clipboard</p></div></div><p><b>Got 90 seconds? Then listen to CEO &amp; managing director, Steven Yatomi-Clarke tell us about their company news.</b></p>\n<p>Prescient Therapeutics (ASX:PTX) develop novel, personalised therapies for a range of cancers.</p>\n<p>The company has a broad pipeline of personalised cancer treatments, comprising CAR-T and targeted therapies, for a range of different cancers. With licensed technologies from and in collaboration with world-leading cancer centers in the US and Australia.</p>\n<p>In August Prescient <span><b>signed a deal with Thermo Fisher Scientific</b></span> to accelerate development and commercialisation of the OmniCAR platform.<span> </span></p>\n<p>Thermo Fisher is a world leader in cell and gene technologies, and the agreement’s development plan will evaluate the potential of using automated, closed cell therapy solutions to develop a novel process of manufacturing cell therapies on Prescient’s OmniCAR platform using non-viral methods.</p>\n<p>We gave Steven Yatomi-Clarke, CEO &amp; Managing Director of Prescient Therapeutics, 90 seconds to tell us more about the recent announcement</p>\n<p><b>Have a good idea for our next 90 Seconds With segment? Email us at [email protected]</b></p>\n<span></span><div></div><div><span>Read More</span>AusbiotechBiotechHealth</div><div></div><div><div><div><img height=\"40\" src=\"https://stockhead.com.au/wp-content/themes/stockhead_lee_mic_v2/images/social-share/check-icon.png\" width=\"40\"/></div><div><p>Link copied to clipboard</p></div></div>\n<div>\n<div></div>\n<div>\n<div>\n<button></button>\n<div>\n<div>\n<h2>SUBSCRIBE</h2><p>Get the latest Stockhead news delivered free to your inbox.</p> </div>\n<div>\n<div>\n<div>\n<p>\"<span>*</span>\" indicates required fields</p>\n</div><form action=\"/stockhead-tv/90-seconds-with-steven-yatomi-clarke-prescient-therapeutics-asxptx/\" enctype=\"multipart/form-data\" method=\"post\" novalidate=\"\" target=\"gform_ajax_frame_2\">\n<div><div><div><label for=\"input_2_1\">Name<span><span>*</span></span></label><div><input aria-invalid=\"false\" aria-required=\"true\" placeholder=\"Name\" type=\"text\" value=\"\"/> </div></div><div><label for=\"input_2_2\">Email<span><span>*</span></span></label><div>\n<input aria-invalid=\"false\" aria-required=\"true\" placeholder=\"Email\" type=\"email\" value=\"\"/>\n</div></div><fieldset><div><i></i><span>Hidden</span></div><legend>Email Lists</legend><div><div><div>\n<input checked=\"checked\" type=\"checkbox\" value=\"Morning Update\"/>\n<label for=\"choice_2_5_1\">Morning Update</label>\n</div><div>\n<input checked=\"checked\" type=\"checkbox\" value=\"Lunch Update\"/>\n<label for=\"choice_2_5_2\">Lunch Update</label>\n</div><div>\n<input checked=\"checked\" type=\"checkbox\" value=\"Market Close Update\"/>\n<label for=\"choice_2_5_3\">Market Close Update</label>\n</div><div>\n<input checked=\"checked\" type=\"checkbox\" value=\"Weekend Update\"/>\n<label for=\"choice_2_5_4\">Weekend Update</label>\n</div></div></div></fieldset><div><label for=\"input_2_3\"></label><div></div></div></div></div>\n<div> <input type=\"submit\" value=\"Submit\"/> <input type=\"hidden\" value=\"form_id=2&amp;title=&amp;description=&amp;tabindex=0\"/>\n<input type=\"hidden\" value=\"1\"/>\n<input type=\"hidden\" value=\"2\"/>\n<input type=\"hidden\" value=\"\"/>\n<input type=\"hidden\" value=\"WyJbXSIsImQ5ODZkNzIwYjIxZjU4YzcxYzQzNTI1YjUzYTViYTYxIl0=\"/>\n<input type=\"hidden\" value=\"0\"/>\n<input type=\"hidden\" value=\"1\"/>\n<input type=\"hidden\" value=\"\"/>\n</div>\n</form>\n</div>\n<p>\n\t\t\t\t\t\t\t\t\t\tIt's free. Unsubscribe whenever you want.\n\t\t\t\t\t\t\t\t\t</p>\n</div>\n</div>\n<div>\n<p><span>Read our privacy policy</span></p>\n</div>\n</div>\n</div>\n</div>\n</div><div> <h3>Featured Companies</h3> <ul><li> <span>ASX: PTX</span> <span>Prescient Therapeutics </span> </li></ul></div><div> <div> <h2>You might be interested in</h2> </div> <div><article> <div> <img height=\"169\" loading=\"lazy\" sizes=\"(max-width: 300px) 100vw, 300px\" src=\"https://stockhead.com.au/wp-content/uploads/2021/08/Screen-Shot-2021-08-10-at-11316-pm-300x169.jpg\" srcset=\"https://stockhead.com.au/wp-content/uploads/2021/08/Screen-Shot-2021-08-10-at-11316-pm-300x169.jpg 300w, https://stockhead.com.au/wp-content/uploads/2021/08/Screen-Shot-2021-08-10-at-11316-pm-1024x576.jpg 1024w, https://stockhead.com.au/wp-content/uploads/2021/08/Screen-Shot-2021-08-10-at-11316-pm-768x432.jpg 768w, https://stockhead.com.au/wp-content/uploads/2021/08/Screen-Shot-2021-08-10-at-11316-pm-610x343.jpg 610w, https://stockhead.com.au/wp-content/uploads/2021/08/Screen-Shot-2021-08-10-at-11316-pm-640x360.jpg 640w, https://stockhead.com.au/wp-content/uploads/2021/08/Screen-Shot-2021-08-10-at-11316-pm.jpg 1200w\" width=\"300\"/> </div> <header> <p>90 Seconds With...</p> <h2>90 Seconds With… Steven Yatomi-Clarke from Prescient Therapeutics (ASX:PTX)</h2> <p> <span> <time datetime=\"2021-08-10 13:15:38\">August 10, 2021</time> <time august=\"\" datetime=\"2021-08-10 13:20:23\"> </time></span> |      <span> <span> Stockhead TV </span> </span> </p> </header></article><article> <div> <img height=\"169\" loading=\"lazy\" sizes=\"(max-width: 300px) 100vw, 300px\" src=\"https://stockhead.com.au/wp-content/uploads/2020/10/1-2-300x169.jpg\" srcset=\"https://stockhead.com.au/wp-content/uploads/2020/10/1-2-300x169.jpg 300w, https://stockhead.com.au/wp-content/uploads/2020/10/1-2-1024x576.jpg 1024w, https://stockhead.com.au/wp-content/uploads/2020/10/1-2-768x432.jpg 768w, https://stockhead.com.au/wp-content/uploads/2020/10/1-2-610x343.jpg 610w, https://stockhead.com.au/wp-content/uploads/2020/10/1-2-640x360.jpg 640w, https://stockhead.com.au/wp-content/uploads/2020/10/1-2.jpg 1280w\" width=\"300\"/> </div> <header> <p>StockTalk</p> <h2>ASX small caps leading the fight against cancer</h2> <p> <span> <time datetime=\"2020-10-08 07:01:59\">October 8, 2020</time> <time datetime=\"2020-10-08 07:05:43\" october=\"\"> </time></span> |      <span> <span> Dr. Nigel Finch </span> </span> </p> </header></article><article> <div> <img height=\"169\" loading=\"lazy\" sizes=\"(max-width: 300px) 100vw, 300px\" src=\"https://stockhead.com.au/wp-content/uploads/2022/08/ASX-health-stocks-roundup.-Picture-Getty-Image-300x169.jpg\" srcset=\"https://stockhead.com.au/wp-content/uploads/2022/08/ASX-health-stocks-roundup.-Picture-Getty-Image-300x169.jpg 300w, https://stockhead.com.au/wp-content/uploads/2022/08/ASX-health-stocks-roundup.-Picture-Getty-Image-1024x576.jpg 1024w, https://stockhead.com.au/wp-content/uploads/2022/08/ASX-health-stocks-roundup.-Picture-Getty-Image-768x432.jpg 768w, https://stockhead.com.au/wp-content/uploads/2022/08/ASX-health-stocks-roundup.-Picture-Getty-Image-610x343.jpg 610w, https://stockhead.com.au/wp-content/uploads/2022/08/ASX-health-stocks-roundup.-Picture-Getty-Image-640x360.jpg 640w, https://stockhead.com.au/wp-content/uploads/2022/08/ASX-health-stocks-roundup.-Picture-Getty-Image.jpg 1200w\" width=\"300\"/> </div><span>Trending</span> <header> <p>Health &amp; Biotech</p> <h2>ASX Health Stocks: <a href=\"https://laohu8.com/S/IMM.AU\">Immutep</a> now patently Japanese; Patrys preps Phase 1 trial of brain cancer drug</h2> <p> <span> <time datetime=\"2022-08-30 13:13:57\">August 30, 2022</time> <time august=\"\" datetime=\"2022-08-30 13:13:57\"> </time></span> |      <span> <span> Eddy Sunarto </span> </span> </p> </header></article> </div></div>\n<div></div>\n<div></div>\n<div><h2>Sponsored Articles</h2></div>\n</main>\n</div></body></html>","source":"stockheads_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>90 Seconds With… Steven Yatomi-Clarke, Prescient Therapeutics (ASX:PTX)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n90 Seconds With… Steven Yatomi-Clarke, Prescient Therapeutics (ASX:PTX)\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-08-31 03:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://stockhead.com.au/stockhead-tv/90-seconds-with-steven-yatomi-clarke-prescient-therapeutics-asxptx/><strong>Stockheads</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Link copied to clipboardGot 90 seconds? Then listen to CEO & managing director, Steven Yatomi-Clarke tell us about their company news.\nPrescient Therapeutics (ASX:PTX) develop novel, personalised ...</p>\n\n<a href=\"https://stockhead.com.au/stockhead-tv/90-seconds-with-steven-yatomi-clarke-prescient-therapeutics-asxptx/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4141","symbol_name":"半导体产品","start_time":0,"source_url":"https://stockhead.com.au/stockhead-tv/90-seconds-with-steven-yatomi-clarke-prescient-therapeutics-asxptx/","article_id":"2263104414","we_media_id":null,"thumbnails":["https://stockhead.com.au/wp-content/uploads/2022/08/90SW-Prescient-Therapeutics-Thumbnail-640x360.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2263104414","pubTimestamp":1661887209,"columns":[],"sourceInfo":{"source_id":"stockheads_stock","name":"Stockheads"},"weMediaInfo":null,"summary":"Link copied to clipboardGot 90 seconds? Then listen to CEO & managing director, Steven Yatomi-Clarke","collect":0,"end_time":0,"defaultTopTitle":"stockhead.com.au","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4141":"半导体产品","BK4526":"热门中概股","ASX":"日月光半导体"},"translate_title":"90秒与…史蒂文Yatomi-Clarke，先见之明治疗学（ASX：PTX）","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ASX":1,"PTX":1},"content_text":"Link copied to clipboardGot 90 seconds? Then listen to CEO & managing director, Steven Yatomi-Clarke tell us about their company news.\nPrescient Therapeutics (ASX:PTX) develop novel, personalised therapies for a range of cancers.\nThe company has a broad pipeline of personalised cancer treatments, comprising CAR-T and targeted therapies, for a range of different cancers. With licensed technologies from and in collaboration with world-leading cancer centers in the US and Australia.\nIn August Prescient signed a deal with Thermo Fisher Scientific to accelerate development and commercialisation of the OmniCAR platform. \nThermo Fisher is a world leader in cell and gene technologies, and the agreement’s development plan will evaluate the potential of using automated, closed cell therapy solutions to develop a novel process of manufacturing cell therapies on Prescient’s OmniCAR platform using non-viral methods.\nWe gave Steven Yatomi-Clarke, CEO & Managing Director of Prescient Therapeutics, 90 seconds to tell us more about the recent announcement\nHave a good idea for our next 90 Seconds With segment? Email us at [email protected]\nRead MoreAusbiotechBiotechHealthLink copied to clipboard\n\n\n\n\n\n\n\nSUBSCRIBEGet the latest Stockhead news delivered free to your inbox. \n\n\n\n\"*\" indicates required fields\n\nName* Email*\n\nHiddenEmail Lists\n\nMorning Update\n\n\nLunch Update\n\n\nMarket Close Update\n\n\nWeekend Update\n\n  \n\n\n\n\n\n\n\n\n\n\n\n\t\t\t\t\t\t\t\t\t\tIt's free. Unsubscribe whenever you want.\n\t\t\t\t\t\t\t\t\t\n\n\n\nRead our privacy policy\n\n\n\n\n Featured Companies  ASX: PTX Prescient Therapeutics    You might be interested in       90 Seconds With... 90 Seconds With… Steven Yatomi-Clarke from Prescient Therapeutics (ASX:PTX)   August 10, 2021   |        Stockhead TV         StockTalk ASX small caps leading the fight against cancer   October 8, 2020   |        Dr. Nigel Finch       Trending  Health & Biotech ASX Health Stocks: Immutep now patently Japanese; Patrys preps Phase 1 trial of brain cancer drug   August 30, 2022   |        Eddy Sunarto     \n\n\nSponsored Articles","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}